NewAmsterdam Pharma Company N. V. is a late-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, particularly those with unmet needs in cholesterol management. The company’s primary mission is to address gaps in existing treatments by offering safe, well-tolerated, and convenient oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C) who do not achieve adequate control with current standard-of-care therapies. At the core of its pipeline is obicetrapib, a next-generation cholesteryl ester transfer protein (CETP) inhibitor designed to lower LDL-C levels as an adjunct to statin therapy. The company is also exploring obicetrapib’s potential in other indications, including Alzheimer’s disease, leveraging its mechanism of action to target cholesterol-related pathways in neurodegenerative conditions.

NewAmsterdam Pharma Company N. V. generates revenue through partnerships, milestone payments, and future commercialization of its lead drug candidate, obicetrapib. The company has entered into an exclusive licensing agreement with Menarini Group, granting rights to commercialize obicetrapib in Europe, the United Kingdom, and Switzerland. Under this agreement, NewAmsterdam received an upfront payment of €115 million, with additional milestone payments and royalties tied to regulatory approvals and sales. Once obicetrapib receives marketing approval, the company expects to earn royalties on net sales in the licensed territories, ranging from low double digits to mid-twenties as a percentage of revenue. In the United States, the company plans to commercialize obicetrapib independently, positioning itself to capture value from direct sales to healthcare providers, pharmacies, and payors.

The company operates through the following segments:

• Cardiometabolic Disease: This segment focuses on the development and commercialization of obicetrapib for patients with atherosclerotic cardiovascular disease (ASCVD) and heterozygous familial hypercholesterolemia (HeFH) who have elevated LDL-C levels despite maximally tolerated statin therapy. Obicetrapib is being evaluated as both a monotherapy and a fixed-dose combination (FDC) with ezetimibe, an existing cholesterol absorption inhibitor. The company has completed multiple Phase 3 trials, including BROADWAY, BROOKLYN, and TANDEM, demonstrating statistically significant reductions in LDL-C with a tolerability profile comparable to placebo. A pivotal Phase 3 cardiovascular outcomes trial, PREVAIL, is ongoing to assess obicetrapib’s impact on major adverse cardiovascular events (MACE).

• Neurodegenerative Disease: This segment explores obicetrapib’s potential in Alzheimer’s disease, driven by preclinical and early clinical evidence suggesting CETP inhibition may mitigate cholesterol accumulation in the brain, a known risk factor for neurodegeneration. The company has completed a Phase 2a trial in patients with early Alzheimer’s disease and the ApoE4 genotype, observing reductions in biomarkers associated with cognitive decline. A larger Phase 2 trial is planned for 2026 to further evaluate obicetrapib’s efficacy in this indication.

NewAmsterdam Pharma Company N. V. operates in the highly competitive cardiovascular and metabolic disease market, where it faces established players with approved LDL-C-lowering therapies. Key competitors include Amgen (Repatha), Regeneron (Praluent), Novartis (Leqvio), and Esperion Therapeutics (Nexletol/Nexlizet), all of which offer injectable or oral non-statin therapies. The company’s competitive advantages lie in obicetrapib’s oral administration, strong LDL-C-lowering efficacy, and favorable tolerability profile. Unlike injectable PCSK9 inhibitors, obicetrapib’s once-daily oral formulation may improve patient adherence, while its demonstrated reductions in LDL-C, lipoprotein(a), and other atherogenic particles position it as a potential best-in-class therapy. Additionally, the fixed-dose combination with ezetimibe could offer synergistic benefits, further differentiating obicetrapib from existing treatments. The company’s strategic partnership with Menarini provides a pathway to commercialization in Europe, reducing execution risk in key markets.

The company’s customer base primarily consists of patients with ASCVD and HeFH who require additional LDL-C-lowering therapy beyond statins. These patients are typically managed by cardiologists, lipidologists, and primary care physicians. In Europe, Menarini will commercialize obicetrapib to healthcare providers, hospitals, and pharmacies, while NewAmsterdam retains direct commercialization rights in the United States. The company also targets payors, including government healthcare programs and private insurers, to secure favorable reimbursement and market access. While specific customer names are not disclosed, the company’s focus on high-risk patient populations with unmet needs positions it to address a significant gap in the current treatment landscape.